Vical Incorporated (NASDAQ:VICL) has been assigned a $9.00 price target by analysts at HC Wainwright in a research note issued on Wednesday, August 9th. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 270.37% from the company’s current price.
Separately, Rodman & Renshaw restated a “buy” rating and issued a $9.00 price target on shares of Vical in a report on Monday, June 12th.
Shares of Vical (NASDAQ VICL) opened at 2.43 on Wednesday. The firm’s market capitalization is $27.71 million. Vical has a one year low of $2.05 and a one year high of $4.33. The stock’s 50 day moving average price is $2.59 and its 200 day moving average price is $2.35.
Vical (NASDAQ:VICL) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.02. Vical had a negative return on equity of 26.09% and a negative net margin of 92.02%. The business had revenue of $3.42 million during the quarter, compared to the consensus estimate of $3.35 million. Analysts expect that Vical will post ($1.05) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Vical Incorporated (VICL) PT Set at $9.00 by HC Wainwright” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.com-unik.info/2017/08/19/vical-incorporated-vicl-given-a-9-00-price-target-at-hc-wainwright-updated.html.
Several hedge funds and other institutional investors have recently bought and sold shares of VICL. New York State Common Retirement Fund increased its position in Vical by 83.6% in the second quarter. New York State Common Retirement Fund now owns 130,706 shares of the biotechnology company’s stock worth $354,000 after buying an additional 59,504 shares during the last quarter. Renaissance Technologies LLC increased its position in Vical by 9.9% in the fourth quarter. Renaissance Technologies LLC now owns 392,509 shares of the biotechnology company’s stock worth $903,000 after buying an additional 35,500 shares during the last quarter. Finally, FMR LLC increased its position in Vical by 1.8% in the fourth quarter. FMR LLC now owns 1,006,875 shares of the biotechnology company’s stock worth $2,316,000 after buying an additional 17,967 shares during the last quarter. Institutional investors and hedge funds own 22.90% of the company’s stock.
Vical Company Profile
What are top analysts saying about Vical Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vical Incorporated and related companies.